The Rare Disease Actions Forum (RDAF) amended its membership conditions

    29 Aug, 2017

    In a decision taken in May 2017, the RDAF board amended the Forum’s membership conditions. The RDAF membership is now open to the following categories of actors: Patient organizations in the area of rare diseases; not-for-profit structures or organizations focused on rare diseases; companies that develop and/or commercialize treatments or diagnostics, or provide related services in the area of rare diseases; healthcare institutions and professionals active in the area of rare diseases; private companies providing services or products linked to rare diseases; and health insurance companies. This decision aims to reinforce the RDAF’s multistakeholder approach to finding solutions to facilitate access to therapies for patients with rare diseases in Switzerland.

    Continue reading

    Boehringer Ingelheim joins the Rare Disease Action Forum

    We are delighted to announce Boehringer Ingelheim as new member of the Rare Disease Action Forum. Boehringer Ingelheim’s membership fortifies RDAF's multi-stakeholder base, alongside other members from industry, patient organizations, healthcare professionals, and...